Tvardi Therapeutics (NASDAQ:TVRD) Releases Quarterly Earnings Results, Misses Estimates By $0.49 EPS

Key Points

• Tvardi Therapeutics reported a quarterly EPS of ($1.00), missing estimates by ($0.49).
• The company has a negative net margin of 595.39% and return on equity of 710.04%, indicating significant financial challenges.
• Tvardi's stock has a twelve-month range of $8.13 to $34.31, with analysts giving it a consensus rating of "Moderate Buy" and an average target price of $64.25.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.49), Zacks reports. Tvardi Therapeutics had a negative net margin of 595.39% and a negative return on equity of 710.04%.

Tvardi Therapeutics Stock Performance

Shares of TVRD stock traded up $0.05 during trading on Thursday, hitting $23.79. 11,668 shares of the company were exchanged, compared to its average volume of 29,214. Tvardi Therapeutics has a twelve month low of $8.13 and a twelve month high of $34.31. The business's 50-day moving average is $25.04.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of hedge funds have recently modified their holdings of TVRD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tvardi Therapeutics in the second quarter valued at about $43,000. Marshall Wace LLP acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at about $583,000. New York State Common Retirement Fund bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $92,000. JPMorgan Chase & Co. acquired a new position in Tvardi Therapeutics in the second quarter worth approximately $39,000. Finally, Geode Capital Management LLC acquired a new position in Tvardi Therapeutics in the second quarter worth approximately $2,617,000. 44.66% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Wall Street Zen upgraded Tvardi Therapeutics to a "hold" rating in a research report on Saturday, May 24th. Oppenheimer assumed coverage on shares of Tvardi Therapeutics in a research note on Wednesday, May 21st. They issued an "outperform" rating and a $65.00 price objective on the stock. Cantor Fitzgerald started coverage on shares of Tvardi Therapeutics in a research report on Friday, July 11th. They issued an "overweight" rating and a $52.00 price target on the stock. Raymond James Financial assumed coverage on Tvardi Therapeutics in a report on Monday, July 14th. They issued an "outperform" rating and a $62.00 target price on the stock. Finally, Piper Sandler initiated coverage on shares of Tvardi Therapeutics in a research report on Thursday, June 12th. They issued an "overweight" rating and a $78.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Tvardi Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $64.25.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.